ARF1 and urogenital neoplasm: These data have demonstrated for the first time that, by virtue of its ability to activate oncogenic MAPK pathway, ARF1 plays a crucial role in prostate tumorigenesis and thus, may represent a novel therapeutic target for prostate cancer.